Related Experiment Video

Updated: Dec 3, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K

Isatuximab for the treatment of relapsed/refractory multiple myeloma

Paul G Richardson1, Meral Beksaç2, Ivan Špička3

  • 1Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute , Boston, MA, USA.

Expert Opinion on Biological Therapy
|October 28, 2020
PubMed
Abstract

Insights

Isatuximab, a CD38 monoclonal antibody, offers a new treatment option for relapsed/refractory multiple myeloma. It shows a manageable safety profile and is being evaluated in further combinations for improved patient outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Multiple myeloma patients often face relapses and treatment resistance despite new therapies.
  • Novel treatment strategies are crucial for improving outcomes in relapsed/refractory multiple myeloma.

Purpose of the Study:

  • To review the development and clinical investigation of isatuximab for relapsed/refractory multiple myeloma.
  • To summarize the mechanism of action, efficacy, and safety of isatuximab.

Main Methods:

  • Review of published data on isatuximab's development and clinical trials.
  • Summary of isatuximab's mechanism of action, efficacy, and safety profile.

Main Results:

  • Isatuximab is approved in combination with pomalidomide/dexamethasone for specific relapsed/refractory multiple myeloma patients.
  • Isatuximab has a manageable safety profile, with infusion reactions as the most common adverse events.

Conclusions:

  • Isatuximab represents a valuable therapeutic option for relapsed/refractory multiple myeloma.
  • Ongoing evaluations of isatuximab in combination regimens aim to further enhance treatment efficacy.
Keywords:
CD38isatuximabmonoclonal antibodymultiple myelomarelapsed/refractory

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K